Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Niladri Aichbhaumik

Allergy & Immunology Saint Paul, MN Medical Doctor

NPI 1437379369 CMS profile 20425

565 Snelling Ave S, Saint Paul, MN 55116

Open in the dashboard

General payments

$14,769

160 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$53,200 paid to institutions, not to them · program years 2023–2024

Through program year 2025, Niladri Aichbhaumik of Saint Paul, MN is reported in the CMS Open Payments database as having received $14,769 across 160 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $53,200 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 80th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,176 32
2024 General $346 19
2023 General $4,116 28
2022 General $1,243 25
2021 General $1,157 20
2020 General $1,542 15
2019 General $4,190 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Niladri Aichbhaumik
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Niladri Aichbhaumik were reported at $2,176. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Niladri Aichbhaumik Allergy & Immunology median Middle half National median
2019 $4,190 $594 $163–$1,512 $163
2020 $1,542 $426 $106–$1,233 $114
2021 $1,157 $638 $157–$1,708 $132
2022 $1,243 $790 $205–$1,961 $149
2023 $4,116 $852 $220–$2,147 $160
2024 $346 $865 $203–$2,267 $164
2025 $2,176 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. CSL Behring $5,606 25 payments
  2. Shire North American Group Inc $3,944 7 payments
  3. Blueprint Medicines Corporation $1,348 3 payments
  4. BioCryst US Sales Co., LLC $1,022 10 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $955 9 payments
  6. Pharming Healthcare, Inc. $227 7 payments
  7. Regeneron Healthcare Solutions, Inc. $184 11 payments
  8. Genzyme Corporation $183 12 payments
  9. Amgen Inc. $153 9 payments
  10. Phadia US Inc. $141 7 payments
  11. Other $1,007 60 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $7,977 4 payments
  2. Food and Beverage $2,625 146 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,656 2 payments
  4. Honoraria $1,285 2 payments
  5. Travel and Lodging $1,139 2 payments
  6. Education $87 4 payments
Products named General payments · program years 2019–2025
  1. TAKHZYRO Immunology $3,901 2 payments
  2. Andembry $1,687 5 payments
  3. AYVAKIT $1,348 3 payments
  4. Orladeyo $1,022 10 payments
  5. TAKHZYRO Genetic Disease $928 8 payments
  6. RUCONEST $227 7 payments
  7. DUPIXENT Immunology $186 12 payments
  8. DUPIXENT Inflammation And Immunology $184 11 payments
  9. ImmunoCAP $141 7 payments
  10. Haegarda $139 10 payments
  11. Other $1,321 81 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

1,343

Median for Internal Medicine: 777

Drug cost

$1,028,606

Median for Internal Medicine: $73,373

Branded share of claims

36.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Takhzyro Lanadelumab-Flyo Brand 13 $682,503
Dupixent Pen Dupilumab Brand 19 $90,132
Xolair Omalizumab Brand 13 $72,199
Breo Ellipta Fluticasone/Vilanterol Brand 39 $26,151
Arnuity Ellipta Fluticasone Furoate Brand 51 $21,489
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 32 $15,064
Mometasone Furoate Generic 98 $13,741
Qvar Redihaler Beclomethasone Dipropionate Brand 31 $13,557
Spiriva Respimat Tiotropium Bromide Brand 16 $11,439
Fluticasone Propionate Hfa Fluticasone Propionate Brand 33 $11,204

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$57,780

Of which drugs: $30,554

Medicare patients

138

Average age 70

Services billed

3,077

81 women, 57 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 46%
Arthritis 39%
Depression 20%
Osteoporosis 15%
Ischemic heart disease 14%
Chronic kidney disease 14%
Cancer 14%
Diabetes 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 12 12 $982

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUCALA
  • GlaxoSmithKline, LLC. $61
$61 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $30
  • GENZYME CORPORATION $15
$45 19 —
TEZSPIRE
  • Amgen Inc. $35
$35 — —
Sajazir
  • Cycle Pharmaceuticals Inc $22
$22 — —
ACTIMMUNE
  • Amgen Inc. $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

160 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Minnesota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record